Welcome to LookChem.com Sign In|Join Free
  • or
Tetrahydro-2H-thiopyran-3-one is an organic compound that falls under the category of cyclic thioketones. It is characterized by a tetrahydrothiopyran ring with an oxo substituent, making it a fundamental structure present in numerous naturally occurring compounds, particularly sulfur-containing antibiotics. As the parent hydride of thiopyran, it holds promise for applications in organosulfur chemistry, with its potential uses and roles in various chemical reactions being the subject of ongoing scientific investigation.

19090-03-0

Post Buying Request

19090-03-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

19090-03-0 Usage

Uses

Used in Pharmaceutical Industry:
Tetrahydro-2H-thiopyran-3-one is used as a key intermediate in the synthesis of various pharmaceutical compounds, particularly in the development of sulfur-containing antibiotics. Its presence in naturally occurring compounds makes it a valuable component in the creation of new drugs with potential therapeutic applications.
Used in Organosulfur Chemistry:
Tetrahydro-2H-thiopyran-3-one is used as a building block in organosulfur chemistry, allowing for the synthesis of a wide range of sulfur-containing organic compounds. Its versatility in chemical reactions makes it a valuable asset in the development of new materials and compounds with potential applications in various industries.
Used in Chemical Research:
Tetrahydro-2H-thiopyran-3-one is used as a subject of study in chemical research, where its potential applications and roles in various chemical reactions are being explored. This ongoing research aims to uncover new ways to utilize Tetrahydro-2H-thiopyran-3-one in the creation of novel materials and compounds with potential applications in various fields.

Check Digit Verification of cas no

The CAS Registry Mumber 19090-03-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,9,0,9 and 0 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 19090-03:
(7*1)+(6*9)+(5*0)+(4*9)+(3*0)+(2*0)+(1*3)=100
100 % 10 = 0
So 19090-03-0 is a valid CAS Registry Number.
InChI:InChI=1/C5H8OS/c6-5-2-1-3-7-4-5/h1-4H2

19090-03-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name thian-3-one

1.2 Other means of identification

Product number -
Other names Dihydro-thiopyran-3-on

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:19090-03-0 SDS

19090-03-0Relevant academic research and scientific papers

SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF

-

, (2018/02/28)

The present invention relates to compounds according to Formula (I-1) and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

3,5-Disubstituted-indole-7-carboxamides as IKKβ Inhibitors: Optimization of Oral Activity via the C3 Substituent

Kerns, Jeffrey K.,Busch-Petersen, Jakob,Fu, Wei,Boehm, Jeffrey C.,Nie, Hong,Muratore, Michael,Bullion, Ann,Lin, Guoliang,Li, Huijie,Davis, Roderick,Lin, Xichen,Lakdawala, Ami S.,Cousins, Rick,Field, Rita,Payne, Jeremy,Miller, David D.,Bamborough, Paul,Christopher, John A.,Baldwin, Ian,Osborn, Ruth R.,Yonchuk, John,Webb, Edward,Rumsey, William L.

supporting information, p. 1164 - 1169 (2018/11/23)

IκB kinase β (IKKβ or IKK2) is a key regulator of nuclear factor kappa B (NF-κB) and has received attention as a therapeutic target. Herein we report on the optimization of a series of 3,5-disubstituted-indole-7-carboxamides for oral activity. In doing so

Synthesis of Cyclic α-Diazo-β-keto Sulfoxides in Batch and Continuous Flow

McCaw, Patrick G.,Buckley, Naomi M.,Eccles, Kevin S.,Lawrence, Simon E.,Maguire, Anita R.,Collins, Stuart G.

, p. 3666 - 3679 (2017/04/11)

Diazo transfer to β-keto sulfoxides to form stable isolable α-diazo-β-keto sulfoxides has been achieved for the first time. Both monocyclic and benzofused ketone derived β-keto sulfoxides were successfully explored as substrates for diazo transfer. Use of continuous flow leads to isolation of the desired compounds in enhanced yields relative to standard batch conditions, with short reaction times, increased safety profile, and potential to scale up.

FUSED TRICYCLIC COMPOUNDS FOR USE AS INHIBITORS OF JANUS KINASES

-

Page/Page column 107, (2013/03/26)

The invention provides novel compounds of formula (I) having the general formula (I) wherein R1, V, W, X, Y and Z are as described herein. Accordingly, the compounds may be provided in pharmaceutically acceptable compositions and used for the treatment of immunological or hyperproliferative disorders.

Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2

De Savi, Chris,Morley, Andrew D.,Nash, Ian,Karoutchi, Galith,Page, Ken,Ting, Attilla,Gerhardt, Stefan

supporting information; experimental part, p. 271 - 277 (2012/02/16)

Directed screening has identified a novel series of non-zinc binding MMP13 inhibitors that possess good levels of activity whilst demonstrating excellent selectivity over related MMPs. A lead optimisation campaign has delivered compounds with enhanced MMP

INDOLE CARBOXAMIDES AS IKK2 INHIBITORS

-

Page/Page column 96, (2008/12/04)

The invention is directed to novel indole carboxamide compounds. Specifically, the invention is directed to compounds according to formula (I): wherein R1, R2, R3, R4, and m are as defined herein. The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, such as rheumatoid arthritis, asthma, rhinitis, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

SPIROCYCLOPROPYL PIPERIDINE DERIVATIVES

-

Page/Page column 79, (2009/01/20)

Disclosed herein is at least one piperidine derivative, at least one pharmaceutical composition comprising at least one piperidine derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith

The search for TCP analogues binding to the low affinity PCP receptor sites in the rat cerebellum

Hamon, Jacques,Espaze, Florence,Vignon, Jacques,Kamenka, Jean-Marc

, p. 125 - 135 (2007/10/03)

With the aim of obtaining selective ligands of the low affinity binding sites of [3H]-1-[1-(2-thienyl)cyclohexyl]piperidine ([3H]TCP) in the rat cerebellum, oxygen and sulfur atoms were introduced in the TCP structure and derivatives to obtain analogues with a lowered lipophilicity. These compounds, and others already obtained, were assayed comparatively to determine their affinities for three sites labeled with [3H]TCP: one in the forebrain, the originally described PCP receptor, and two in the rat cerebellum. Lowering the lipophilicity and modifying the hetero-aromatic moiety yielded some ligands with increased affinity for the low affinity sites in the rat cerebellum and decreased affinity for the high affinity sites in the forebrain. Particularly, two compounds displaying both a high affinity and a good selectivity might be valuable tools to elucidate the pharmacology of the low affinity PCP sites labeled with [3H]TCP in the rat cerebellum.

Enzymes in organic syntheses. 19. Evaluation of the stereoselectivities of horse liver alcohol dehydrogenase; catalyzed oxidoreductions of hydroxy- and ketothiolanes, -thianes, and -thiepanes

Jones, J. Bryan,Schwartz, Harold M.

, p. 1574 - 1579 (2007/10/02)

The specificity of horse liver alcohol dehydrogenase (HLADH) with respect to unsubstituted five-, six-, and seven-membered ring 3- and 4-thiaketone and -thiaalcohol substrates has been examined.The enzyme is found to have a broad tolerance of the structural variations within this series.HLADH also exhibits encouraging (up to 46percent) enantiotopic and enantiomeric specifity in preparative-scale reduction and oxidation reactions of the heterocyclic ketones and alcohols respectively.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 19090-03-0